Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluxadoline for Diabetic Diarrhea
NCT04313088Phase 3Withdrawn
- Sponsor
- Temple University
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of eluxadoline in diarrhea (2 arms), sponsored by Temple University. Primary endpoint: Proportion of days with improved bowel movements at 140 days. Planned start Jul 2022; status: withdrawn.
02
Drugs
eluxadoline
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT04313088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313088.